Fiber intake and plasminogen activator inhibitor-1 in type 2 diabetes: Look AHEAD (Action for Health in Diabetes) trial findings at baseline and year 1.

Fiber intake and plasminogen activator inhibitor-1 in type 2 diabetes: Look AHEAD (Action for Health in Diabetes) trial findings at baseline and year 1.

Plasminogen activator inhibitor 1 (PAI-1) is increased in obese patients with type 2 diabetes and can contribute, independently of traditional factors, with an increased risk of cardiovascular disease. fiber intake can reduce levels of PAI-1. We examined the association of dietary fiber intake and changes with PAI-1 prior to and during the intensive intervention lifestyle (ILI) to lose weight in 1701 FRONT View (Health Action in Diabetes) participants with diet, fitness, and PAI-1 data at baseline and 1 year.

Look AHEAD is a randomized trial of cardiovascular disease in 5145 overweight / obese patients with type 2 diabetes, comparing ILI (≥7% weight reduction goals baseline) with a control group of diabetes support and education. ILI participants are encouraged to consume vegetables, fruits, and whole grain products are low in sugar and fat. At baseline, the average fiber intake is 17.9 g / day. Each 8.3 g / day higher fiber intake was associated with a 9.2% lowering PAI-1 levels (P = 0.008); This association persisted after adjustment weight and fitness (P = 0.03). The higher initial intake of fruit (P = 0.019) and high-fiber wheat and cereals (P = 0.029) associated with lower levels of PAI-1.

Although it managed to increase the weight and physical fitness at 1 year, the ILI in Look AHEAD resulted in a small increase in the intake of fiber (4.1 g / day, compared with -2.35 g / day with a diabetes support and education) were not associated with PAI- 1 changes (P = 0.34). Only 31.3% of ILI participants (39.8% female, 19.1% male) meet daily fiber intake recommendations. Increasing fiber intake in overweight / obese individuals with diabetes are interested in weight loss challenge. future studies evaluate changes in fiber intake during weight loss interventions is guaranteed.

Fiber intake and <em>plasminogen</em> <em>activator</em> <em>inhibitor</em>-1 in type <em>2</em> diabetes: Look AHEAD (Action for Health in Diabetes) trial findings at baseline and year 1.
Fiber intake and plasminogen activator inhibitor-1 in type 2 diabetes: Look AHEAD (Action for Health in Diabetes) trial findings at baseline and year 1.

The interaction of cell adhesion molecules CHL1 with vitronectin, integrins, and plasminogen driving inhibitors – two promote the development induced CHL1- neurite and neuronal migration.

The cell adhesion molecule close homolog of L1 (CHL1) plays an important functional role in the developing and adult nervous system. In looking for a partner binding that mediates the function of diverse and sometimes opposite of CHL1, extracellular matrix-associated protein vitronectin and plasminogen activator inhibitor-2 (PAI-2) was identified as a partner interaction CHL1 novel and tested for involvement in CHL1-dependent functions during mouse development cerebellum.

CHL1-induced cerebellar neurite and cell migration results in postnatal days 6-8 were inhibited by a peptide derived CHL1 consisting of integrin binding RGD motif, and with antibodies against vitronectin or some integrins, showed integrin-mediated pathway-dependent vitronectin. A PAI-2 derived peptide, or antibody against PAI-2, urokinase type of plasminogen activator (uPA), uPA receptor, and some of the integrin reduces cell migration.

CHL1 colocalized with vitronectin, PAI-2, and some of the integrin in cerebellar granule cells, show an association between these proteins. Interestingly, on a slightly earlier age 4-5 d, cerebellar neurons do not depend on CHL1 to neuritogenesis and cell migration. However, the differentiation of progenitor cells into neurons at this stage depends on CHL1-CHL1 homophilic interaction.

Cat IgG Fab2, unlabeled (non-immune, isotype control) purified
20002-4-UL 0.1 mg
EUR 164
Cat IgM-Biotin conjugate (non-immune, isotype control) purified
20002-5-B 0.1 mg
EUR 225
Cat IgM, unlabeled (non-immune, isotype control) purified
20002-5-UL 0.1 mg
EUR 164
FluoroQuest™ Anti-fading Kit II *Optimized for Plate Imaging*
20003 1 kit
EUR 132
  • R-phrase: R20, R21, R22
  • H-Phrase: H303, H313, H333
  • Symbol for dangerous compounds: Xn
  • UNSPEC Code: 12352200
Hamster IgG, purified (Syrian, isotype control)
20003-1 1 mg
EUR 141
Hamster IgG-Biotin conjugate, isotype control (Syrian)
20003-1-B 100 test
EUR 164
Hamster IgG-Cy5 conjugate, isotype control (Syrian)
20003-1-Cy5 50 tests
EUR 225
Hamster IgG-FITC conjugate, isotype control (Syrian)
20003-1-F 100 tests
EUR 164
Hamster IgG-HRP conjugate, isotype control (Syrian)
20003-1-HP 100 tests
EUR 164
Hamster IgG-R-PE-Cy5.5 conjugate, isotype control (Syrian)
20003-1-PC5 50 tests
EUR 250
Hamster IgG-R-PE conjugate, isotype control (Syrian)
20003-1-PE 50 tests
EUR 225
Hamster IgG, purified (Armenian, Isotype control)
20003-1AH 1 mg
EUR 263
Hamster (Syrian, non-immune) Serum IgM, purified (Syrian)
20003-2-1 0.5 mg
EUR 225
FluoroQuest™ Mounting Medium with DAPI
20004 50 mL
EUR 132
  • R-phrase: R20, R21, R68
  • H-Phrase: H303, H313, H340
  • Symbol for dangerous compounds: T
  • UNSPEC Code: 12352200
G. Pig IgG, purified (non-immune, serum, Isotype control)
20004-1 1 mg
EUR 141
G. Pig IgM, purified (non-immune, serum, Isotype control)
20004-2-1 0.5 mg
EUR 225
G. Pig IgG Fc-Biotin conjugate (isotype control, non-immune) purified
20004-3-B 0.1 mg
EUR 225
G. Pig IgG Fc-FITC conjugate (isotype control, non-immune) purified
20004-3-F 0.1 mg
EUR 225
G. Pig IgG Fc-HRP conjugate (isotype control, non-immune) purified
20004-3-HP 0.1 mg
EUR 225
G. Pig IgG Fc unlabeled (isotype control, non-immune) purified
20004-3-UL 0.5 mg
EUR 202
G. Pig IgA, purified (non-immune, serum, Isotype control)
20004-5-1 100 ug
EUR 347
G. Pig IgG-Biotin conjugate (isotype control)
20004-B 100 ug
EUR 202
G. Pig IgG-FITC conjugate (isotype control)
20004-F 100 ug
EUR 202
G. Pig IgG-HRP conjugate (isotype control)
20004-HP 100 ug
EUR 202
Rat IgG, purified (Whole, non-immune) (isotype control)
20005-1 1 mg
EUR 141
Rat IgG purified (isotype control)
20005-1-200 0.5 ml
EUR 103
Rat IgG Fab fragment, purified (isotype control)
20005-1-FAB 1 mg
EUR 164
Rat IgG F(ab')2 fragment, purified (isotype control)
20005-1-FAB2 1 mg
EUR 202
Rat IgG (Fc) fragment, purified (isotype control)
20005-1-FC 0.5 mg
EUR 250
Rat IgG (Fc)-Biotin Conjuagte (isotype control), purified
20005-1-FC-B 0.1 mg
EUR 225
Rat IgG (Fc)-FITC Conjuagte (isotype control), purified
20005-1-FC-F 0.1 mg
EUR 225
Rat IgG (Fc)-HRP Conjuagte (isotype control), purified
20005-1-FC-HP 0.1 mg
EUR 225
Rat IgG, purified (Whole, non-immune) (isotype control)
20005-10 10 mg
EUR 408
Rat IgG1 cunonjugated (isotype control)
20005-11 100 ug
EUR 164
Rat IgG1-Biotin conjugate (isotype control)
20005-11-B 100 ug
EUR 202
Rat IgG1-FITC conjugate (isotype control)
20005-11-F 100 ug
EUR 225
Rat IgG1-HRP conjugate (isotype control)
20005-11-HP 100 ug
EUR 202
Rat IgG1-R-PE-Cy5.5 conjugate (isotype control)
20005-11-PC5 25 tests
EUR 202
Rat IgG1-R-PE conjugate (isotype control)
20005-11-PE 25 tests
EUR 202
Rat IgG2a unconjugated (isotype control)
20005-12 100 ug
EUR 164
Rat IgG2a-APC conjugate (isotype control)
20005-12-APC 25 tests
EUR 202
Rat IgG2a-Biotin conjugate (isotype control)
20005-12-B 100 ug
EUR 202
Rat IgG2a-FITC conjugate (isotype control)
20005-12-F 100 ug
EUR 225
Rat IgG2a-HRP conjugate (isotype control)
20005-12-HP 100 ug
EUR 202
Rat IgG2a-R-PE-Cy5.5 conjugate (isotype control)
20005-12-PC5 25 tests
EUR 213
Rat IgG2a-R-PE conjugate (isotype control)
20005-12-PE 25 tests
EUR 202
Rat IgG2b unconjugated (isotype control)
20005-13 100 ug
EUR 164
Rat IgG2b-Biotin conjugate (isotype control)
20005-13-B 100 ug
EUR 202
Rat IgG2b-FITC conjugate (isotype control)
20005-13-F 100 ug
EUR 225
Rat IgG2b-HRP conjugate (isotype control)
20005-13-HP 100 ug
EUR 202
Rat IgG2b-R-PE-Cy5.5 conjugate (isotype control)
20005-13-PC5 25 tests
EUR 213
Rat IgG2b-R-PE conjugate (isotype control)
20005-13-PE 25 tests
EUR 202
Rat IgG2c-Biotin conjugate (isotype control)
20005-14-B 100 ug
EUR 225
Rat IgG2c-FITC conjugate (isotype control)
20005-14-F 100 ug
EUR 225
Rat IgG2c-HRP conjugate (isotype control)
20005-14-HP 100 ug
EUR 225
Rat IgG2c-R-PE conjugate (isotype control)
20005-14-PE 50 tests
EUR 250
Rat IgG2c unonjugated (isotype control)
20005-14-UL 100 ug
EUR 164
Rat IgM (non-immune), purified (isotype control)
20005-2-1 0.1 mg
EUR 164
Rat IgM-Biotin conjugate (isotype control)
20005-21-B 100 ug
EUR 225
Rat IgM-FITC conjugate (isotype control)
20005-21-F 100 ug
EUR 225
Rat IgM-HRP conjugate (isotype control)
20005-21-HP 100 ug
EUR 225
Rat IgM-R-PE conjugate (isotype control)
20005-21-PE 25 tests
EUR 202
Rat IgA (non-immune), purified (isotype control)
20005-3-1 25 ug
EUR 225
Rat IgG, purified (Isotype control)
20005-5 5 mg
EUR 286
Rat IgG-Agarose conjugate(aff matrix)
20005-AS-1 0.5 ml
EUR 164
Rat IgG-Biotin conjugate (isotype control) (Isotype control)
20005-B 100 ug
EUR 164
Rat IgG-FITC conjugate (isotype control) (Isotype control)
20005-F 100 ug
EUR 164
Rat IgG-HRP conjugate (isotype control) (Isotype control)
20005-HP 100 ug
EUR 164
Rat IgG-PE conjugate (isotype control) (Isotype control)
20005-PE 25 tests
EUR 202
FluoroQuest™ Fluorescence Signal Enhancing Solution
20006 5 mL
EUR 132
  • R-phrase: R20, R21, R68
  • H-Phrase: H303, H313, H340
  • Symbol for dangerous compounds: T
  • UNSPEC Code: 12352200
Sheep IgG, purified (isotype control)
20006-1 1 mg
EUR 141
Sheep IgG-Biotin Conjugate (isotype control, non-immune), purified
20006-1-B 0.5 mg
EUR 202
Sheep IgG-FITC Conjugate (isotype control, non-immune), purified
20006-1-F 0.5 mg
EUR 202
Sheep IgG-HRP Conjugate (isotype control, non-immune), purified
20006-1-HP 0.5 mg
EUR 202
Sheep IgM purified (isotype control)
20006-2 1 mg
EUR 347
Sheep IgM-Biotin Conjugate (non-immune) control, purified
20006-2-B 0.1 mg
EUR 225
Sheep IgA purified (isotype control)
20006-3 100 ug
EUR 286
Sheep IgG Fc-Biotin Conjugate (isotype control, non-immune), purified
20006-4-B 0.5 mg
EUR 202
Sheep IgG Fc-FITC Conjugate (isotype control, non-immune), purified
20006-4-F 0.5 mg
EUR 202
Sheep IgG Fc-HRP Conjugate (isotype control, non-immune), purified
20006-4-HP 0.5 mg
EUR 202
Sheep IgG Fc unlabeled (isotype control, non-immune), purified
20006-4-UL 0.5 mg
EUR 202
Human IgG, purified (serum, non-immune, isotype control)
20007-1-1 1 mg
EUR 141
Human IgG, purified (serum, non-immune, isotype control)
20007-1-100 100 mg
EUR 895
Human IgG, purified (serum, non-immune, isotype control)
20007-1-25 25 mg
EUR 651
Human IgG, purified (serum, non-immune, isotype control)
20007-1-5 5 mg
EUR 286
Human IgG-Biotin conjugate (isotype control, non-immune), purified
20007-1-B 0.5 mg
EUR 225
Human IgG (>98%, non-immune, control, Liquid @ 10 mg/ml, azide free, bulk size)
20007-1-BL-1 10 ml Ask for price
Human IgG (>98%, non-immune, control, powder, azide free, bulk size)
20007-1-BP-1 1 g
EUR 651
Human IgG (>98%, non-immune, control, powder, azide free, bulk size)
20007-1-BP-10 10 g
EUR 4313
Human IgG-FITC conjugate (isotype control, non-immune), purified
20007-1-F 0.5 mg
EUR 225
Human IgG Fab fragment, purified
20007-1-FAB 1 mg
EUR 202
Human IgG Fab fragment-Biotin Conjugate, purified
20007-1-FAB-B 0.1 mg
EUR 202
Human IgG Fab fragment-FITC Conjugate, purified
20007-1-FAB-F 0.1 mg
EUR 202
Human IgG Fab fragment-HRP Conjugate, purified
20007-1-FAB-HP 0.1 mg
EUR 202
Human IgG F(ab')2 fragment, purified
20007-1-FAB2 1 mg
EUR 202
Human IgG Fab2 fragment-Biotin Conjugate, purified
20007-1-FAB2-B 0.1 mg
EUR 202

These observations suggest that homophilic CHL1 trans-interactions regulate the differentiation of progenitor cells nerve at the stage of early postnatal, while heterophilic trans-interaction CHL1 with vitronectin, integrins, and the system is plasminogen activator set neuritogenesis and migration of nerve cells at a later stage after the birth of cerebellar morphogenesis , Thus, in a very narrow time window in postnatal cerebellar development, the different types of molecular interactions mediated by CHL1 underlying the diverse functions of these proteins.